Neumora Therapeutics (NMRA) Research & Development (2022 - 2026)

Neumora Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $38.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 25.99% year-over-year to $38.6 million; the TTM figure through Mar 2026 stood at $162.5 million (down 21.61% YoY), while the FY2025 annual figure was $176.1 million, down 12.37% from the prior year.
• Research & Development for Q1 2026 stood at $38.6 million, down from $44.7 million in the prior quarter.
• The five-year high for Research & Development was $60.6 million in Q3 2024, with the low at $22.5 million in Q3 2022.
• The 5-year median for Research & Development is $40.5 million (2025), against an average of $40.3 million.
• The sharpest annual moves came in 2023 and 2025: Research & Development jumped 84.49% in 2023, then sank 33.17% in 2025.
• Neumora Therapeutics' Research & Development stood at $23.5 million in 2022, then jumped by 65.22% to $38.9 million in 2023, then climbed by 18.14% to $45.9 million in 2024, then decreased by 2.71% to $44.7 million in 2025, then slipped by 13.59% to $38.6 million in 2026.
• Business Quant data shows NMRA's Research & Development at $38.6 million in Q1 2026, $44.7 million in Q4 2025, and $40.5 million in Q3 2025.